A novel technique for treating GBM first underwent a phase 1 clinical trial with patients who had recurrence of their cancers after their primary treatment, and was published in the journal ...

BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that researchers will ...

Half of patients with GBM present with headaches at diagnosis, which is attributed to increases in intracranial pressure (Table 2). 11 Papilledema, now rarely seen because imaging is typically ...

Metabolic profiling using Seahorse analysis showed that CCR5 inhibition reduced oxygen consumption rate (OCR) in a dose-dependent manner, consistent with modulation of glycolytic and metabolic ...

Cintredekin besudotox targets IL-13 alpha-2 receptor in glioblastoma, aiming to spare healthy brain tissue while destroying cancer cells. Orphan drug designation offers benefits like lower fees and ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Variation over time and interdependence between disease progression and death among patients with glioblastoma (GBM) on RTOG 0525. Background: Current standard treatment for GBM consists in ...

A new liposome-based therapy delivers two drugs directly to glioblastoma cells, overcoming delivery barriers. When combined ...

The glioblastoma multiforme (GBM) treatment market size is on a steep growth trajectory, rising from $2.73 billion in 2025 to $ ...